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Abstract
ADAM17 (a disintegrin and metalloproteinase) is a membrane-anchored metalloproteinase that regulates the release of
EGFR-ligands, TNFa and other membrane proteins from cells. ADAM17 can be rapidly activated by a variety of signaling
pathways, yet little is known about the underlying mechanism. Several studies have demonstrated that the cytoplasmic
domain of ADAM17 is not required for its rapid activation by a variety of stimuli, including phorbol esters, tyrosine kinases
and some G-protein coupled receptors. However, phosphorylation of cytoplasmic residue T735 was recently reported as a
crucial step for activation of ADAM17 by IL-1b and by the p38 MAP-kinase pathway. One possible mechanism to reconcile
these results would be that T735 has an inhibitory role and that it must be phosphorylated as a pre-requisite for the
activation of ADAM17, which would then proceed via a mechanism that is independent of its cytoplasmic domain. To test
this hypothesis, we performed rescue experiments of Adam172/2 cells with wild type and mutant forms of ADAM17.
However, these experiments showed that an inactivating mutation (T735A) or an activating mutation (T735D) of
cytoplasmic residue T735 or the removal of the cytoplasmic domain of ADAM17 did not significantly affect the stimulation
of ADAM17 by IL-1b or by activation of MAP-kinase with anisomycin. Moreover, we found that the MAP-kinase inhibitor
SB203580 blocked activation of cytoplasmic tail-deficient ADAM17 and of the T735A mutant by IL-1b or by anisomycin,
providing further support for a model in which the activation mechanism of ADAM17 does not rely on its cytoplasmic
domain or phosphorylation of T735.
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Introduction
ADAM17 (a disintegrin and metalloproteinase 17) is a
membrane-anchored metalloproteinase that has crucial roles in
regulating the release of the pro-inflammatory cytokine tumor
necrosis factor a (TNFa) [1–4] as well as the bioavailability of
ligands of the epidermal growth factor receptor (EGFR) [5–9], and
has been implicated in the ectodomain shedding of numerous
other membrane proteins (reviewed in [5,10]). ADAM17 is
important for proper development of the skin, lung, mammary
gland and heart valves [6–9], and it has emerged as a critical
mediator of TNF-dependent endotoxin shock, pathological
neovascularization and of intestinal inflammation and regenera-
tion in adult mice [2,11,12]. The sheddase activity of ADAM17
can be rapidly activated in response to a variety of different stimuli
in cell-based assays [8,13–20], yet much remains to be learned
about the underlying mechanism. Reddy et al. [13] reported that
phorbol ester-stimulated shedding of TNFa and other membrane
proteins from Adam172/2 mouse embryonic fibroblasts (mEFs)
could be restored by a mutant form of ADAM17 lacking its
cytoplasmic domain, including all cytoplasmic phosphorylation
sites, thereby demonstrating that the activation of ADAM17 by
phorbol 12-myristate 13-acetate (PMA) does not require cytoplas-
mic phosphorylation. Later, a similar approach was used to show
that the response of ADAM17 to treatment of cells with other
stimuli, including physiological stimuli such as epidermal growth
factor (EGF), TNFa, lysophosphatidic acid, thrombin, benzoyl-
ATP and fibroblast growth factor 7 as well as oncogenic Src, the
calcium ionophore Ionomycin, or the mercurial compound
acetyloxy-(4-aminophenyl)mercury [15,16,21] required the trans-
membrane domain, but not the cytoplasmic domain of ADAM17.
Even though the cytoplasmic domain of ADAM17 is not
necessary for its ability to respond to the stimuli listed above,
several studies have demonstrated that this domain is phosphor-
ylated when cells are treated with stimuli such as PMA, EGF,
nerve growth factor [22], lipopolysaccharide [23], fibroblast
growth factor, fetal bovine serum (FBS) [24], the GPCR agonist
gastrin-related peptide [25], transforming growth factor b [26] and
interleukin-1b (IL-1b) [27]. Moreover, Diaz-Rodriguez et al. [22]
showed that a threonine to alanine mutation at cytoplasmic
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processing of neurotrophic tyrosine kinase receptor A compared
to wild type ADAM17 following treatment with PMA. More
recently, Xu and Derynck reported that the T735.A mutation
almost completely abrogated the ability of ADAM17 to respond to
stimulation by IL-1b or anisomycin, which activate the p38
MAPK pathway [27]. Additionally, Xu and Derynck provided
evidence for a direct interaction between p38 and the ADAM17
cytoplasmic domain, and therefore proposed that phosphorylation
of T735 by p38 MAPK is a key event in the activation of
ADAM17 in response to IL-1b.
The finding that ADAM17 requires cytoplasmic phosphoryla-
tion of T735 in order to respond to activation by IL-1b, but not by
PMA [27], and the observation that the cytoplasmic domain is
dispensable for activation of ADAM17 by PMA [13], EGF, TNFa,
lysophosphatidic acid, thrombin, Ionomycin, benzoyl-ATP [15],
oncogenic Src [21] and activation of fibroblast growth factor
receptor 2b [16] raised questions about the cause for these
apparent discrepancies. One possibility was that ADAM17 relies
on distinct mechanisms to respond to different stimuli, such that
the cytoplasmic domain is dispensable for activation by the stimuli
listed above, but not for stimulation by IL-1b or anisomycin.
Another possible explanation was that the cytoplasmic residue
T735 functions to prevent the activation of ADAM17, and that
this residue must be phosphorylated as a pre-requisite for the
activation of ADAM17. In this scenario, the T735.A mutation
would block the ability of ADAM17 to respond to stimulation,
whereas removal of the cytoplasmic domain would relieve any
inhibitory effect of T735 on ADAM17, thus allowing it to respond
to various stimuli. The main goal of the present study was to
further define the role of T735 and of the cytoplasmic domain of
ADAM17 in its regulation by IL-1b and anisomycin.
Materials and Methods
Ethics Statement
The isolation of primary mEFs was approved by the Internal
Animal Care and Use Committee of the Hospital for Special
Surgery (protocol # 09-10-22M, approval date 10/27/2010).
Reagents
All reagents were from Sigma unless indicated otherwise.
Bisindolylmaleimide I (BIM I), SB203580, and anisomycin were
from Calbiochem, and recombinant mouse IL-1b was purchased
from R&D Systems or Peprotech. Both IL-1b preparations were
tested for their ability to activate ADAM17 in parallel and were
found to cause equivalent activation. Marimastat was kindly
provided by Dr. Ouathek Ouerfelli (Sloan-Kettering Institute,
New York, NY).
Expression constructs
Alkaline phosphatase (AP)-tagged transforming growth factor a
(TGFa), betacellulin (BTC), CD62L, and a TNFa cleavage site
construct as well as C-terminally hemagglutinin (HA)-tagged
murine ADAM17 and ADAM17DC lacking its cytoplasmic
domain have been previously described [15,28,29]. The cDNA
for human TNFa was cloned from the pFLAG-CMV2 [30] into
the pCDNA3.1(-) A myc/his vector. The cDNA for wild type (wt)
HA-tagged murine ADAM17 was used to generate a catalytically
inactive Glu406 to Ala406 mutant (ADAM17E.A-HA) as well as
the cytoplasmic Thr735 to Ala735 mutant (T735A) to abolish this
phosphorylation site, or the Thr735 to Asp735 mutant (T735D) to
mimic the phosphorylated threonine. Separate PCR reactions
were performed to create untagged T735A and T735D mutants of
ADAM17. The cDNA for human interleukin-1 receptor 2 (IL-
1R2) was cloned into the pAPtag5 vector to create an IL-1R2-AP
fusion protein (Residue 14 to 398). Successful introduction of the
desired mutations and the absence of other mutations were
confirmed by sequencing. Constructs expressing human wild type
ADAM17 and the human ADAM17-T735A mutant were
generously provided by Drs. P. Xu and R. Derynck (Univ. of
California, San Francisco).
Cell lines and culture conditions
Wild type mEFs immortalized with large T-antigen (Figure 1A)
have been previously described [2]. Primary Adam172/2 mEFs
(Figures 1B–D, 2A–C and 3A,B) were isolated as described [8,31]
and genotyped by Western blotting with polyclonal antibodies
against ADAM17 [32]. The ADAM17-deficient M2 CHO cell line
[33,34] (Figure 3C,D) was obtained from Dr. J. Arribas (Vall
d’Hebron Institute of Oncology, Barcelona, Spain). All cells were
grown in Dulbecco’s modified Eagle’s medium supplemented with
10% FBS and antibiotics, and were transfected using GenJet
(SignaGen Laboratories) for 5 hours, and then transferred to
growth medium for overnight recovery. All shedding experiments
were performed one or two days after transfection.
Shedding Assays
Prior to ectodomain shedding experiments, the transfected cells
were serum-starved in low-serum OptiMem (Gibco) for two hours
(mEFs) or 24 hours (M2 CHO cells). For experiments with
inhibitors, the cells were pre-incubated with the inhibitor for
10 minutes before the addition of the stimulating agent for an
additional 30 minutes. SB203580 was used at 10 mM, BIM I at
4 mM, IL-1b at 5 ng/ml, PMA at 25 ng/ml and anisomycin at
1 mM. The shedding of AP-tagged proteins was measured as
previously described [8,31]. In brief, after stimulation, conditioned
media was collected and cells were lysed in 2.5% TritonX-100,
1 mM EDTA, 1 mM 1,10 phenanthroline. AP activity was
determined by incubating the conditioned media and lysates with
p-nitrophenyl phosphate (Thermo Scientific) at 37uC followed by
measuring the OD405. Shed TNFa was detected using the optEIA
Human TNFa ELISA kit (BD Biosciences) according to the
manufacturer’s instructions.
Western Blotting
For Western blot analysis, transfected cells were lysed in 1%
TritonX-100 in PBS with 10 mM 1,10 phenanthroline, 5 mM
marimastat and 16protein inhibitor cocktail [35]. Glycoproteins
were enriched using Concanavalin A-agarose lectin beads (GE
Healthcare) and then separated on 10% SDS-polyacrylamide gels.
Proteins were transferred to nitrocellulose membranes (Pall Life
Sciences) and probed with anti-HA antibodies (Covance), or
antibodies against the cytoplasmic domain of ADAM17 [32]
followed by HRP-coupled anti-mouse-IgG or anti-rabbit-IgG
(Promega) and detected using enhanced chemoluminescence
(ECL, Amersham).
Statistical Analysis
All experiments were conducted at least in triplicate and the
results were averaged. Standard error of the mean was calculated
using Microsoft Excel. A paired Student’s t-test was used to
compare the results generated from experiments with identically
transfected cells with or without stimulation and inhibition. When
the comparison was between identically treated cells transfected
with different constructs; an unpaired t-test was used. A p-value of
,0.05 was considered statistically significant.
IL-1ß Stimulates ADAM17 Lacking Cytoplasmic Domain
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In order to determine whether IL-1b stimulates ADAM10 or
ADAM17 in wild type mEFs, we measured the release of the
alkaline phosphatase-tagged ADAM17 substrates TGFa [7,8],
TNFa [1–3], CD62L [36], IL-1R2 [13], and of the ADAM10
substrate betacellulin [8] from these cells following incubation with
5 ng/ml IL-1b for 30 minutes. Treatment with IL-1b stimulated
the shedding of the ADAM17 substrates, but not of the ADAM10
substrate, demonstrating that under these conditions IL-1b
activates ADAM17, but not ADAM10 (Figure 1A).
To corroborate that ADAM17 is required for the IL-1b-
stimulated shedding of TGFa in mEFs, primary Adam172/2
mEFs were transfected with TGFa-AP together with wild type or
mutant forms of ADAM17. No increase in TGFa-AP shedding
was observed upon stimulation with IL-1b when the catalytically
inactive HA-tagged ADAM17-E.A mutant was co-transfected.
However, co-transfection of HA-tagged ADAM17 was sufficient to
Figure 1. Stimulation of wild type and T735 mutant forms of ADAM17 by IL-1ß and anisomycin. A) Wild type mEFs were transfected
with alkaline phosphatase-tagged substrates to monitor the sheddase activity of ADAM17 (TGFa, TNFa, CD62L and IL-1R2) or ADAM10 (BTC) and
stimulated with IL-1ß (5 ng/ml) for 30 minutes. The release of the AP-tagged ADAM10 or ADAM17 substrates into the culture supernatant was
determined as described in materials and methods. B) Adam172/2 primary mEFs were transfected with TGFa-AP and either HA-tagged or untagged
forms of the catalytically inactive ADAM17-E406A (EA), wild type ADAM17 (WT), or ADAM17 carrying point mutations at residue T735 (T735A or
T735D), as indicated. The amount of TGFa-AP released in 30 minutes from untreated cells (black bars) or from cells stimulated with IL-1ß (5 ng/ml,
light grey bars) or anisomycin (1 mM, dark grey bars) was determined as described in materials and methods. C) Western blots of untagged or HA-
tagged forms of ADAM17 (EA, WT, T735A or T735D) expressed in Adam172/2 mEFs were probed with antibodies against the cytoplasmic domain of
ADAM17 (top panel) or the HA-tag (middle panel), or against ADAM9 as a loading control. D) Shedding of transfected human TNFa from Adam172/2
mEFs rescued with WT or the T735A, T735D or EA mutant forms of ADAM17. The amount of TNFa released into the conditioned media from
unstimulated cells or cells stimulated with IL-1b (5 ng/ml) in 30 minutes was determined by ELISA. All data represent the average of at least three
separate experiments, and the error bars correspond to +/2 standard error of the mean (sem). Asterisks indicate a significant increase upon addition
of the stimulatory agent (students t-test, p,0.05). NS indicates that no significant difference was found between the indicated conditions.
doi:10.1371/journal.pone.0031600.g001
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PLoS ONE | www.plosone.org 3 February 2012 | Volume 7 | Issue 2 | e31600Figure 2. Effect of inhibitors of p38 MAPK or PKC on stimulated shedding by ADAM17T735A and ADAM17DC. A) Adam172/2 mEFs
were co-transfected with TGFa-AP and murine WT ADAM17, EA, T735A or DC mutants, and either not treated (black bars) or stimulated with IL-1b
(5 ng/ml, light grey bars) or anisomycin (1 mM, dark grey bars), in the presence or absence of 10 mM of the p38 MAPK inhibitor SB203580 (SB203) as
indicated, with DMSO serving as a control. Constitutive and stimulated shedding of TGFa-AP was rescued by cotransfection with WT ADAM17 as well
as the T735A and DC mutants, but not by the inactive EA mutant. There was no significant difference between the constitutive or stimulated
shedding of TGFa-AP from Adam172/2 mEFs rescued with WT compared to the T735A or DC mutant of ADAM17. IL-1b and anisomycin-stimulated
shedding of TGFa-AP in cells rescued with WT, T735 or DC was blocked to a comparable extent by 10 mM of the p38 MAPK inhibitor SB203580. B)
TGFa-AP shedding from Adam172/2 cells rescued with WT ADAM17, T735A or DC was stimulated to a comparable level by 25 ng/ml PMA
(untreated, black bars, PMA-treated, grey bars), and the stimulation could be blocked by the PKC inhibitor BIM I (4 mM). C) Adam172/2 mEFs
transfected with TGFa together with WT ADAM17 were stimulated with 5 ng/ml IL-1b,1mM anisomycin or 25 ng/ml PMA in the presence or absence
of 4 mM BIM I. BIM I blocked the TGFa-AP shedding stimulated by PMA, but had no significant effect on the shedding stimulated by IL-1b or
anisomycin. All results represent the average values of at least 3 experiments, and the error bars indicate +/2 standard error of the mean (sem).
Asterisks indicate a significant increase upon addition of a stimulus, whereas plus (+) indicates a significant decrease in stimulated shedding upon
introduction of an inhibitor (students t-test, p,0.05).
doi:10.1371/journal.pone.0031600.g002
IL-1ß Stimulates ADAM17 Lacking Cytoplasmic Domain
PLoS ONE | www.plosone.org 4 February 2012 | Volume 7 | Issue 2 | e31600increase constitutive shedding and restore the stimulated shedding
of TGFa in response to treatment with IL-1b or anisomycin
(Figure 1B).
The ability to rescue IL-1b-stimulated shedding of TGFa-AP in
Adam172/2 cells by co-transfection of HA-tagged ADAM17
allowed us to test how mutations of T735 affected the response of
ADAM17 to stimulation with IL-1b or anisomycin. We found that
the ADAM17-T735.A (T735A) as well as the ADAM17-
T735.D (T735D) phosphomimetic mutant were able to rescue
constitutive and IL-1b- or anisomycin-stimulated shedding of
TGFa in Adam172/2 cells (Figure 1B). When we performed
identical rescue experiments with untagged versions of wt
ADAM17, T735A, T735D and of the inactive E.A mutant, the
results were comparable to those obtained with the corresponding
HA-tagged forms of ADAM17, arguing against the possibility that
the HA-tag interferes with regulation of ADAM17 by T735
(Figure 1B). Western blot analysis with antibodies against the HA
tag or the cytoplasmic domain of ADAM17 corroborated similar
expression of the wild type and mutant forms of HA-tagged or
untagged ADAM17 (Figure 1C). Overexpressed ADAM17 was
mainly detected as a pro-form on Western blots, which is
consistent with previous studies [14]. Nevertheless, the relatively
small amounts of mature wild type or mutant forms of ADAM17
produced under these conditions are evidently sufficient to rescue
the shedding defect in Adam172/2 mEFs. Finally, we tested the
shedding of a non-AP tagged ADAM17 substrate, TNFa, using an
ELISA assay. The constitutive and IL-1b-stimulated shedding of
TNFa by the T735 mutants was not significantly different from
that mediated by wt ADAM17 (Figure 1D).
These results suggested that IL-1b activates ADAM17 in a
manner that does not rely on phosphorylation of T735. To
provide additional evidence for this finding, we tested whether the
p38 MAPK inhibitor, SB203580 (10 mM), which blocks IL-1b-
dependent stimulation of ADAM17 [27], also affected the
stimulation of the T735A mutant by IL-1b or anisomycin. As
shown in Figure 2A, SB203580 prevented IL-1b- and anisomycin-
stimulated activation of T735A as effectively as of wt ADAM17.
Similar results were obtained with ADAM17DC( DC), which lacks
the cytoplasmic domain, including all potential phosphorylation
sites (Figure 2A). These results suggest that stimulation of
ADAM17 by IL-1b or anisomycin does not require an interaction
between p38 MAPK and the cytoplasmic domain of ADAM17 or
the presence of T735 or other cytoplasmic phosphorylation sites.
Moreover, we found that the protein kinase C (PKC) inhibitor,
BIM I, blocked PMA-stimulated activation of T735A or DCt oa
similar extent as it blocked activation of wt ADAM17 (Figure 2B),
suggesting that a direct interaction of PKC with the cytoplasmic
domain of ADAM17 is also not necessary for the stimulation of
ADAM17 by PMA [13,14,27]. Additionally, the role of PKC in
p38 MAPK stimulation of ADAM17 was tested by adding BIM I
to TGFa-AP expressing Adam172/2 mEFs rescued with
ADAM17 and treated with IL-1b, anisomycin or PMA
Figure 3. Comparison of TGFa shedding by human wild type ADAM17 and the T735A mutant. A) Adam172/2 mEFs were transfected
with TGFa-AP together with human wild type ADAM17 (hWT) or the human ADAM17-T735A mutant (hT735A). TGFa-AP shedding was measured in
supernatants conditioned for 30 minutes on untreated cells (black bars) or cells treated with 1 mM anisomycin (grey bars). There was no significant
difference between constitutive or anisomycin-stimulated shedding by hT735A compared to hWT ADAM17. B) Western blot analysis with antibodies
against the cytoplasmic domain of ADAM17 demonstrated comparable expression of hWT and hT735A, with ADAM9 serving as a loading control. C)
M2 CHO cells carrying inactivating mutations in both alleles of ADAM17 [37] were transfected with TGFa-AP and the inactive mouse ADAM17EA to
provide a negative control, or hWT or hT735A. Basal shedding of TGFa-AP was restored to comparable levels by the introduction of either hWT or
hT735A. The stimulation of hWT and hT735 by 1 mM anisomycin was weaker in M2 CHO cells than in Adam172/2 mEFs rescued with these
constructs, but there was no significant difference between the anisomycin-stimulated shedding by these two constructs. D) Western blot analysis of
M2 CHO cells with anti-ADAM17 cytotail antibodies shows the expression of the endogenous mutant forms of ADAM17 in untransfected cells, and
similar expression levels of murine ADAM17EA (mEA) compared to human WT or T735A ADAM17. The results in panels A and C represent the average
of at least 3 experiments +/2 sem. Asterisks indicate significant increase upon addition of a stimulus.
doi:10.1371/journal.pone.0031600.g003
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TGFa-AP, but had no significant effect on IL-1b- or anisomycin-
dependent stimulation of ADAM17. These results suggest that
PKC is not required for the activation of ADAM17 by p38
MAPK.
To address the possibility that human and mouse ADAM17
differ in their response to phosphorylation of T735, we performed
rescue experiments with wt human ADAM17 or human
ADAM17-T735A in primary Adam172/2 mEFs or in AD-
AM17-deficient M2 CHO cells [33,34,37], which were also used
by Xu and Derynck [27]. We found no significant difference in the
response of human wt ADAM17 and ADAM17-T735A to
stimulation with anisomycin in Adam172/2 mEFs (Figure 3A)
or in M2 CHO cells, where inactive murine ADAM17EA served
as a negative control (Figure 3C). Western blot analysis confirmed
comparable expression of human wt and T735 ADAM17 in
Adam172/2 mEFs (Figure 3B) and in M2 CHO cells (Figure 3D).
These results argue against a model in which cytoplasmic
phosphorylation is a crucial component of the mechanism of
activation of ADAM17 by IL-1b or anisomycin. Instead, they
support previous studies in which the cytoplasmic domain of
ADAM17 was not required for its response to several other stimuli
[14,15,36,38]. Moreover, they argue against a model in which
T735 is part of an inhibitory mechanism that keeps ADAM17
inactive and that must be phosphorylated as a prerequisite to allow
activation of ADAM17. The outcome of the rescue experiments
were also comparable when shedding of alkaline phosphatase-
tagged TGFa or non-AP tagged TNFa were used as a readout for
the activity of ADAM17, both of which are cleaved almost
exclusively by ADAM17 under the conditions used in our assay
[2,14]. The lack of IL-1b- and anisomycin-stimulated shedding of
TGFa or TNFa from Adam172/2 mEFs rescued with the
inactive ADAM17-E.A demonstrates that no other enzyme can
compensate for the loss of ADAM17 when mEFs are activated
with these stimuli, as previously also shown for several other
stimuli [14,15,36,38]. Finally, essentially identical results were
obtained in rescue experiments with two other ADAM17-deficient
cell types, M2 CHO cells [33,34,37] and Adam172/2 primary
mouse chondrocytes (see Figure S1). Thus, the cause for the
discrepancy between the results presented here and those reported
by Xu and Derynck remains to be established, but could be due to
different experimental conditions. Recently, Li et al. described a
mutant form of ADAM17 carrying a Cys to Tyr mutation in
residue 600 in the cysteine-rich domain (ADAM17-C600Y) that
had low residual activity, which could be substantially increased
when the cytoplasmic domain was deleted [39]. However, Li et al.
observed no increase in the activity of wt ADAM17 upon deletion
of its cytoplasmic domain, which is consistent with our conclusion
that deletion of the cytoplasmic domain of ADAM17 has no
detectable effect on the catalytic activity of the wt protein.
Taken together, stimulation of ADAM17 by IL-1b or
anisomycin appears to be regulated by a mechanism that relies
on activation of p38 MAPK, but does not require phosphorylation
of T735 or the presence of the cytoplasmic domain of ADAM17,
at least under the conditions used here. It is tempting to speculate
that a yet-to-be-identified membrane protein that interacts with
ADAM17 is responsible for its rapid posttranslational activation.
There is considerable interest in ADAM17 as a therapeutic target
because it regulates EGFR signaling and the release of TNFa.
Elucidation of the underlying mechanism of its activation could
therefore potentially uncover novel targets for treatment of
diseases such as cancer or rheumatoid arthritis. Our results
suggest that it will be important to explore mechanisms that do not
involve phosphorylation of the cytoplasmic domain of ADAM17
in order to understand the regulation of this principal sheddase for
EGFR-ligands and TNFa.
Supporting Information
Figure S1 Wildtype and mutant ADAM17 constructs
rescue IL-1b-stimulated shedding of alkaline phospha-
tase-tagged TNFa from primary Adam172/2 chondro-
cytes. Adam172/2 chondrocytes were prepared as described by
Gosset et al. [40] with the exception that E18.5 embryos were used
instead of 5-day old mice. The Adam172/2 chondrocytes were
transfected with the wt or mutant forms of ADAM17 and a
reporter construct consisting of an alkaline phosphatase tag
attached to the cleavage site and transmembrane domain of
human TNFa. Stimulation with IL-1b lead to an increase of
shedding activity by wt ADAM17, ADAMT735A or T735D or
ADAM17DC, but not by the catalytically inactive ADAM17EA
mutant. Additionally, IL-1b-stimulated shedding by wt ADAM17
and the T735A, T735D and the DC mutants could be inhibited by
10 mM of the p38 MAPK inhibitor SB203580 (SB203), but not by
the carrier DMSO. These results represent the average of at least 3
experiments +/2 sem. Asterisks indicate significant increase upon
addition of a stimulus.
(TIF)
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